panitumumab

Generic Name: panitumumab

Brand Names: Vectibix

Drug Type: Biotech

Chemical Formula: -

CAS Number: 339177-26-3

Unique Ingredient Identifier: 6A901E312A

Background: Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.

Panitumumab was granted FDA approval on 27 September 2006.

Indication: 美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。

Associated Conditions: Metastatic Colorectal Cancer (CRC)

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations

Phase 2

Completed

Conditions: Cholangiocarcinoma

Interventions: Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Bevacizumab
Drug: Panitumumab

First Posted Date: 2010-09-21

Last Posted Date: 2017-03-13

Lead Sponsor: Vejle Hospital

Target Recruit Count: 88

Registration Number: NCT01206049

Locations: 🇩🇰
Department of Oncology, Vejle Hospital, Vejle, Denmark

CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Phase 2

Completed

Conditions: Gastrointestinal Cancer

Interventions: Drug: Panitumumab

First Posted Date: 2010-09-15

Last Posted Date: 2020-02-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT01202409

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

Phase 2

Terminated

Conditions: Gastroesophageal Adenocarcinoma
Adenocarcinoma of the Distal Esophagus
Adenocarcinomas of the Gastroesophageal Junction
Adenocarcinoma of the Proximal Stomach

Interventions: Drug: Panitumumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: 5FU

First Posted Date: 2010-08-17

Last Posted Date: 2012-12-03

Lead Sponsor: Accelerated Community Oncology Research Network

Target Recruit Count: 1

Registration Number: NCT01182610

Locations: 🇺🇸
Clopton Clinic, Jonesboro, Arkansas, United States

Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Panitumumab

First Posted Date: 2010-08-05

Last Posted Date: 2017-03-20

Lead Sponsor: Amsterdam UMC, location VUmc

Target Recruit Count: 18

Registration Number: NCT01175733

Locations: 🇳🇱
VU University Medical Center, Amsterdam, Netherlands

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Phase 2

Withdrawn

Conditions: Carcinoid Syndrome

Interventions: Drug: Panitumumab

First Posted Date: 2010-07-30

Last Posted Date: 2013-07-26

Lead Sponsor: Boston Medical Center

Registration Number: NCT01172717

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States

Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Colorectal Carcinoma
Colorectal Tumors
Neoplasms, Colorectal

Interventions: Drug: Panitumumab
Drug: Irinotecan
Drug: Everolimus

First Posted Date: 2010-06-08

Last Posted Date: 2017-11-06

Lead Sponsor: The Queen Elizabeth Hospital

Target Recruit Count: 49

Registration Number: NCT01139138

Locations: 🇦🇺
The Queen Elizabeth Hospital, Adelaide, South Australia, Australia

Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: Panitumumab

First Posted Date: 2010-05-21

Last Posted Date: 2019-12-09

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 11

Registration Number: NCT01128387

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Phase 2

Suspended

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Panitumumab
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2010-03-17

Last Posted Date: 2013-03-14

Lead Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH

Target Recruit Count: 134

Registration Number: NCT01088620

Locations: 🇩🇪
LMU-Klinikum der Universität München, Medizinische Klinik München-Innenstadt, München, Germany
🇩🇪
Universitätsklinikum Jena, Klinik für Innere Medizin I, Jena, Germany
🇩🇪
UK-SH, Campus Lübeck, Med. Klinik III, Lübeck, Germany

and more 17 locations

Chemoradiation and Panitumumab for Esophageal Cancer

Phase 2

Completed

Conditions: Adenocarcinoma
Gastro-esophageal Junction Cancer
Squamous Cell Carcinoma
Esophageal Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: panitumumab
Radiation: radiotherapy

First Posted Date: 2010-03-02

Last Posted Date: 2021-04-21

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 78

Registration Number: NCT01077999

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Netherlands

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed
Drug: Panitumumab

First Posted Date: 2010-01-05

Last Posted Date: 2016-05-11

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 70

Registration Number: NCT01042288

Locations: 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

and more 10 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy